Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

PARIS, June 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection). The company also announced topline results of a second Phase 3 study (EDITION II) for new insulin U300 that also demonstrated similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus®.

(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO )

These results are from EDITION I and EDITION II respectively and are part of the EDITION Phase 3 clinical program evaluating the efficacy and safety of the investigational new insulin U300 in people with diabetes.  The EDITION I data was presented at the 73rd Scientific Sessions of the American Diabetes Association.

"To properly manage diabetes, it is critical to control blood sugar and to reduce the risk of low blood sugar events, especially at night," said Matthew Riddle, Professor of Medicine, Division of Endocrinology/Diabetes/Clinical Nutrition, Oregon Health and Science University, U.S., and Principal Investigator for the EDITION I study. "I am encouraged by these findings, and look forward to the results of the full Phase 3 EDITION program, which will further reveal how this investigational basal insulin may help people living with diabetes."

EDITION IAs the first study of the EDITION Phase 3 program, EDITION I evaluated the efficacy and safety of investigational new insulin U300, vs. Lantus® in people with type 2 diabetes using basal pl
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 A study using ... offered a new look at the composition of carotid ... physicians understand and treat the disease, a leading cause ... Baptist Health Lexington between September 2010 and May 2012, ... Journal of the American College of Cardiology (JACC) ...
(Date:9/30/2014)... 30, 2014  HealthLoop® released an app version of ... iOS 8 and allows people to share medical device ... native iOS technologies to enhance the HealthLoop experience for ... with their doctors between visits. "This ... they collect is exciting," says HealthLoop founder Dr. ...
(Date:9/30/2014)...  Georgia-Pacific Professional is a leading provider of ... wide range of away from home applications. Building ... healthcare, including hospitals, long-term care facilities, surgical centers ... healthcare products and solutions to the dental community. ... infection control in the dental office," said ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... (Nasdaq: THOR ), a world leader in device-based ... hearts, today announced that it will report its operating results ... 2010 on Thursday, October 28. The company will ... operating activities open to all interested parties at 1:30 p.m., ...
... 22 Bacterin International Holdings, Inc. (OTC Bulletin ... is scheduled to present at the upcoming Singular Research 5th ... 2010 at 3:20p.m.(PT) at the Luxe Hotel Sunset Boulevard, Los ... Bacterin, and John Gandolfo, Bacterin,s chief financial officer, will review ...
Cached Medicine Technology:Thoratec Schedules Third Quarter Conference Call, Webcast 2Bacterin International to Present at Singular Research 5th Annual Best of the Uncovereds Conference 2
(Date:9/30/2014)... September 30, 2014 Catalent Pharma ... advanced delivery technologies and development solutions for drugs, ... full agenda for the 25th Annual CPhI Worldwide ... October 6th to 9th. , Catalent is showcasing ... expansions during the show, including its facilities in ...
(Date:9/30/2014)... Coast Dental and Orthodontics is ... practice, located at 1010 Shaw Avenue in Clovis, CA. ... services , and specialty dental care including orthodontics, endodontics, ... and convenient dental care, our Clovis dentists also strive ... Coast Dental at 559-777-6113 to schedule an appointment. , ...
(Date:9/30/2014)... September 30, 2014 With accolades like the ... Lash Masters II, Hilaree Brand of My Brand Lashes is ... craft and, more importantly, the ability to teach. She leads ... credentials and a great reputation. , With a background in ... a Master of Aesthetics and as an Instructor. She has ...
(Date:9/30/2014)... NY, September 30, 2014Levothyroxine (L-T4), long the standard ... most patients, but some individuals do not regain ... thyroid physiology may help to explain these differences. ... Association on thyroid hormone replacement reviewed the latest ... to determine whether a change to the current ...
(Date:9/30/2014)... Pittsburgh School of Dental Medicine have been awarded a ... Dental and Craniofacial Research, part of the National Institutes ... roots of cleft lip and cleft palate and to ... the Philippines and Pennsylvania. , Orofacial clefts (OFCs), ... that can form when a baby,s mouth doesn,t develop ...
Breaking Medicine News(10 mins):Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:Coast Dental Clovis Celebrates Grand Opening 2Health News:Coast Dental Clovis Celebrates Grand Opening 3Health News:My Brand Lashes and Lash Affair By J. Paris Merge to Offer Premium Lash and Brow Products and Certifications 2Health News:My Brand Lashes and Lash Affair By J. Paris Merge to Offer Premium Lash and Brow Products and Certifications 3Health News:New hypothyroidism treatment guidelines from American Thyroid Association 2Health News:Pitt team searches for genetic roots of cleft lip, palate 2
... latest advancement in aspirin delivery ... ... has,rolled out Fasprin(R), a patented, 81 milligram aspirin tablet that,dissolves rapidly ... solution for the millions of Americans who maintain a,daily aspirin routine ...
... Formulas No Better than Generic Store-Brand Infant,Formulas, Says Mayo Clinic ... ... GORDONSVILLE, Va., Nov. 13 The Mayo Clinic, a ... every type of complex illness, now offers an online resource ...
... Awareness and Funds to Fight Homelessness in Los ... LOS ANGELES, Nov. 13 United Way of Greater ... to fight homelessness on,Saturday morning, November 17, 2007, by ... Exposition Park near downtown Los Angeles.,HomeWalk will engage participants ...
... Groundbreaking Meeting Brings Together Cancer Funding Organizations, Advocates, Government ... ... Pharmaceutical Industry, NEW YORK, Nov. 13 Leadership ... and advocacy groups met,on November 1-2 along with experts ...
... of America (GSA) has chosen W. Andrew Achenbaum of ... the Donald P. Kent Award. This distinguished honor is ... the highest standards for professional leadership in gerontology through ... society. , The award presentation will take place ...
... chosen Nancy L. Pedersen of Sweden,s Karolinska Institutet to ... to Gerontology. This prize is given annually to an ... new synthesis and perspective or have yielded original and ... literature. , The award presentation will take place at ...
Cached Medicine News:Health News:New, No-Swallow Fasprin(R) Reduces Problems Associated with Daily Aspirin Regimen 2Health News:Mayo Clinic Supports Store-Brand Infant Formulas 2Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 2Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 3Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 2Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 3Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 4
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
... technology allows the grasper ... a shorter length and ... the stone. The Unidex ... one-handed operation. Supplied sterile ...
Bugbee Fulgurating...
Fulgurating Electrode, 2 F...
Medicine Products: